AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

LIFE SCIENCE REIT PLC

AGM Information May 25, 2023

5353_dva_2023-05-25_bac9949f-732d-4f14-ad40-20558c0ad714.html

AGM Information

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 7151A

Life Science REIT PLC

25 May 2023

Life Science REIT plc

(the "Company")

LEI: 213800RG7JNX7K8F7525

25 May 2023

Annual General Meeting ("AGM") Results

The Company announces that at its Annual General Meeting held earlier today all the resolutions set out in the Notice of Annual General Meeting were passed. All resolutions were voted on by way of a poll.  The results of the poll for each resolution were as follows:

Resolution For Against Votes Withheld

(No. of shares)
No. of shares % No. of shares %
1.   To receive and approve the annual report and financial statements 237,307,165 100.00% 10,345 0.00% 19,548
2.   To receive and approve the Directors' remuneration report 236,497,636 99.68% 761,688 0.32% 77,734
3.   To re-elect Claire Boyle as a Director of the Company 227,063,288 95.69% 10,227,912 4.31% 45,858
4.   To re-elect Sally Ann Forsyth as a Director of the Company 197,662,892 90.55% 20,630,888 9.45% 19,043,278
5.   To re-elect Michael Taylor as a Director of the Company 236,321,834 99.59% 969,366 0.41% 45,858
6.   To re-elect Richard Howell as a Director of the Company 236,350,144 99.59% 969,366 0.41% 17,548
7.   To appoint Deloitte LLP as Auditor to the Company 237,257,249 99.97% 63,261 0.03% 16,548
8.   To authorise the Audit and Risk Committee to determine the remuneration of the Auditor to the Company 237,267,855 99.99% 24,345 0.01% 44,858
9.   To approve the Company's dividend payment policy 237,287,855 100.00% 10,345 0.00% 38,858
10.  To authorise the Directors to allot equity securities 228,003,637 96.08% 9,294,563 3.92% 38,858
11.  To authorise the Directors to disapply pre-emption rights* 226,872,038 95.61% 10,420,162 4.39% 44,858
12.  To authorise the Directors to disapply pre-emption rights for the purposes of financing an acquisition or other capital investment* 225,728,875 95.13% 11,563,325 4.87% 44,858
13.  To approve the purchase of the Company's own shares* 227,477,570 95.87% 9,800,639 4.13% 58,849
14.  That a general meeting, other than an AGM, may be called on not less than 14 clear days' notice* 236,894,091 99.83% 404,109 0.17% 38,858

*special resolution

NOTES:
1. All resolutions were passed.
2. Percentages have been rounded to two decimal places.
3. Proxy appointments which gave discretion to the Chair of the AGM have been included in the "For" total for the appropriate resolution.
4. Votes "For" and "Against" any resolution are expressed as a percentage of votes validly cast for that resolution.
5. A "Vote withheld" is not a vote in law and is not counted in the calculation of the percentage of shares voted "For" or "Against" any resolution.
6. The number of shares in issue at 6:00 pm. on 23 May 2023 was 350,000,000 ordinary shares, carrying one vote each, and at that time, the Company did not hold any shares in treasury.
7. The full text of the resolutions passed at the AGM can be found in the Notice of Annual General Meeting which is available on the Company's website at https://lifesciencereit.co.uk/investors/shareholder-information/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGAAMATMTBTBJJ

Talk to a Data Expert

Have a question? We'll get back to you promptly.